Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation

BACKGROUND: Gemtuzumab ozogamicin (GO) administered before allogeneic hematopoietic cell transplantation (alloHCT) has been linked to an increased risk of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). PROCEDURE: This retrospective analysis examined VOD/SOS risk and clinic...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pediatr Blood Cancer
Main Authors: Duncan, Christine, St. Martin, Andrew, Pérez, Waleska S., Steinert, Patricia, Zhang, Mei-Jie, Chirnomas, Deborah, Hoang, Caroline J., Loberiza, Fausto R., Saber, Wael
Formato: Artigo
Idioma:Inglês
Publicado: 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8324076/
https://ncbi.nlm.nih.gov/pubmed/33871892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.29067
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares